SmithKline Beckman Corp said & lt ; Boehringer Mannheim GmbH > signed final agreement develop market new cardiovascular medicine discovered Boehringer .
Under agreement , SmithKline said , responsibility developing product U.S .
Both partner market product U.S. abroad .
Initially , SmithKline said , company concentrate clinical development marketing carvedilol compound treat mild moderate hypertension angina .
An application marketing approval carvedilol submitted West Germany last December , SmithKline said .
Applications expected European market year submission U.S. Food Drug Administration projected 1990 .
It said work also underway thromboxane receptor antagonist , compound could useful accelerating disolution blood clot preventing blod clot occuring heart attack well arterial disease .
The company said two compound clinical evaluation Europe U.S. Reuter & # 3 ; 